Indometacin does not reduce the incidence of heterotopic ossification
Indometacin does not reduce the incidence of heterotopic ossification
Indometacin as prophylaxis for heterotopic ossification after the operative treatment of fractures of the acetabulum
J Bone Joint Surg Br. 2006 Dec;88(12):1613-7Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
127 patients with displaced fractures of the acetabulum were included in this study to examine the effectiveness of indometacin in reducing the incidence of heterotopic ossification (HO). Patients were randomized to receive indometacin sustained released (75 mg) or placebo daily for 6 weeks. After 3 months, there was no significant difference between the two groups for the incidence of HO and rate...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.